BARNSTABLE, MA, September 19, 2013 – (Accesswire) – UV Flu
Technologies, Inc. (OTCQB: UVFT) (the "Company") announced today
that the warning issued this week from the CDC, or Center for
Disease Control, relating to the threats from strains of bacteria
that have grown impervious to bacteria, may only scratch the
surface with respect to the overall threat. The health warning did
estimate that at least 2 million people in this country become
infected with bacteria that are resistant to antibiotics, and that
at least 23,000 people die each year as a result of these
infections. Thousands more die from infections contracted in
hospitals, as well as from other conditions that were complicated
by antibiotic-resistant infections.
"We feel the problem is getting worse, not better," said Jack
Lennon, President of UV Flu Technologies, the manufacturer of the
ViraTech UV-400, an FDA cleared air purifier which kills over 99%
of airborne bacteria with every pass.
"The average person breathes 3,600 gallons of air per day, and
little if any has been treated to kill or trap the airborne
infection and contaminants that enter our lungs every minute we’re
alive. TB, Whooping Cough, MRSA, Staph, and a host of other
airborne bacteria and viruses are growing stronger, in some cases
becoming totally resistant to treatment with antibiotics. Many of
these strains are at epidemic proportions in other countries, and
its’ only a matter of time before they spread to this country,"
said Mr. Lennon.
"Children experience antibiotics at much earlier ages, rarely
have the childhood diseases that most adults had 30-50 years ago,
and they spend 90% of their time indoors, so their immune response
systems are at a disadvantage in fighting off these resistant
strains of bacteria and other contaminants. This combination could
have deadly consequences in the future. A small contraction in the
breathing passages of small children can cut their breathing
60-70%, up to 4 times more severe than a typical adult."
"We feel preventing the spread of these airborne infections is
the first line of defense. Airborne contaminants sink over time,
making surface contamination more severe, so just wiping down
surfaces only addresses part of the problem."
Dr. Walter Kowalski, one of the worlds’ leading authorities on
ultraviolet light, and its ability in killing organic contaminants,
in a report issued in June, 2013, evaluated the ViraTech UV-400
Portable Air Purification Unit, and how effective it was in
utilizing 3 UV lamps and a catalytic kill chamber, with the purpose
of stopping the spread of airborne infection. After evaluating
dozens of competing units, Dr. Kowalski said, “Considering the
ability of the UV-400 to kill all bacteria, viruses, and fungal
spores in a typical sized room, it is clearly among the "Best in
Class" of all devices evaluated.
Further details regarding the Company’s business, acquisitions,
financial reports and agreements are filed as part of the Company’s
continuous public disclosure as a reporting issuer under the
Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission’s ("SEC") EDGAR database. For more
information, visit: www.uvflutech.com, and click on the 5 minute
video describing the ViraTech UV-400[TM].
About UV Flu Technologies, Inc. (OTCQB:
UVFT)
UV Flu Technologies is an innovative developer;
manufacturer and distributor of bio technology products initially
targeting the rapidly growing Indoor Air Quality ("IAQ") industry
sector ($7 billion in 2011). The Company manufactures the ViraTech
UV-400[TM], which utilizes high-intensity ultraviolet radiation
(UV-C) inside a killing chamber that goes beyond filtration to
destroy harmful airborne bacteria, at rates exceeding 99.2% on a
first-pass basis, while also reducing the concentrations of odors,
and VOC’s (volatile organic compounds, such as acetone, benzene,
formaldehyde, etc.) The FDA has issued a coveted Class II
medical listing that enables UV Flu Technologies to market the
product as a medical device. For more information, visit:
http://www.uvflutech.com/.
About RxAir Industries, LLC
RxAir[TM] is the
leading provider of air purification solutions for the medical
industry with hundreds of units in waiting rooms to emergency rooms
in respected medical facilities nationwide. RxAir™ products remove
harmful pathogens from the air in infectious environments for
emergency pandemics through isolation rooms and negative pressure
rooms. The RxAir™ air purification line is 99.97% efficient,
portable, and adaptable, requires zero-maintenance.
http://www.rxair.com/.
Notice Regarding Forward-Looking
Statements
This news release contains "forward-looking statements" as that
term is defined in Section 27A of the United States Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements in this press release which are not
purely historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, the development, costs and results of new
business opportunities. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with new projects and development stage
companies. These forward-looking statements are made as of the date
of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in our annual
report on Form 10-K for the most recent fiscal year, our quarterly
reports on Form 10-Q and other periodic reports filed from
time-to-time with the Securities and Exchange Commission. Executing
the transaction requires further work on structure, management,
governance, and other significant matters. Within the next number
of months, UV Flu’s and RxAir’s management will develop detailed
plans for the Board's further consideration and final
approval.
The completion of the spin-off is subject to a number of
conditions, including final approval of the transaction by each
Board, favorable tax rulings and or opinions of the transaction to
UV Flu and to its shareholders, further due diligence as
appropriate, and the filing and effectiveness of appropriate
filings with the Securities and Exchange Commission ("SEC").
There can be no assurances given that the separation of UV Flu’s
business as described in this announcement will occur. UV Flu will
provide interim updates as appropriate.
ON BEHALF OF THE BOARD
UV Flu Technologies,
Inc.
-----------------------------
John
J. Lennon, President/CEO
Investor Information:
Toll-Free:
1-877-358-5545 (FLU-KILL)
Web: http://www.uvflutech.com/
Retail or Internet Inquires:
Please call our
Corporate Office at: 508-362-5455
SOURCE UV Flu Technologies, Inc.
UV Flu Technologies (CE) (USOTC:UVFT)
Historical Stock Chart
From Jan 2025 to Feb 2025
UV Flu Technologies (CE) (USOTC:UVFT)
Historical Stock Chart
From Feb 2024 to Feb 2025
